PEG-Based T4 Liquid Formulations for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The bioavailability of tetraiodothyronine (T4) in oral pharmaceutical formulations is compromised due to its low water solubility and tendency to form insoluble microaggregates in aqueous media, leading to unpredictable and inconsistent absorption, which contributes to the high failure rate of T4-based treatments.
Innovation Solution
Solubilizing T4 in polyethylene glycols (PEG) creates solvent systems that exceed its low solubility limits, forming soluble micellar nanoaggregates of 50-200 nm, which are easily absorbed, preventing the formation of insoluble microaggregates and ensuring bioavailability, even under dilution and varying pH conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If T4 is formulated in aqueous media, then the formulation is simple and easy to manufacture, but T4 forms insoluble microaggregates leading to poor bioavailability
Solution Approach 1:
The patent uses hydrophilic polymers (solubilisants) as intermediary substances that mediate between the hydrophobic T4 molecule and the aqueous environment. These polymers form soluble complexes with T4, preventing microaggregate formation while maintaining formulation simplicity and manufacturability.
Solution Approach 2:
The patent changes the physical-chemical parameters of the aqueous medium by adding hydrophilic polymers that alter solubility characteristics. This transforms the aqueous environment from one that causes T4 precipitation to one that maintains T4 in soluble form, improving bioavailability without complicating manufacturing.
2Productivity
If T4 concentration is increased in the formulation, then the dosage efficiency improves, but the risk of microaggregate formation increases
Solution Approach 1:
Hydrophilic polymers act as mediators that enable high T4 concentrations to be maintained in soluble form. The polymers surround and solubilize T4 molecules, preventing them from aggregating even at high concentrations, thus maintaining both dosage efficiency and absorption consistency.
Solution Approach 2:
The hydrophilic polymers are added to the formulation beforehand to create a solubilizing environment before T4 is introduced. This preliminary action ensures that when T4 is present at high concentrations, it remains solubilized and does not form microaggregates.
3Speed
If liquid formulation is used, then absorption speed increases, but the formulation complexity increases compared to solid forms
Solution Approach 1:
The patent changes the physical state of T4 from solid to liquid solution form, which inherently increases absorption speed. The addition of hydrophilic polymers maintains T4 in dissolved state, and while this adds formulation components, it enables the speed advantage of liquid formulations.
Solution Approach 2:
The formulation creates a composite liquid system combining T4, hydrophilic polymers, and aqueous medium. This composite material approach enables liquid formulation benefits (fast absorption) while managing complexity through the use of well-characterized polymer excipients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of PEG-based solvent systems significantly enhances the bioavailability of T4 by maintaining high concentrations and preventing aggregation, leading to improved absorption and compliance, particularly in liquid oral formulations.
Implementation Method 1
solubilising T4 in polyethylene glycols produces pharmaceutical formulations which, in an aqueous medium, reach concentrations far exceeding the low water-solubility value of T4, without the formation of a precipitate basically consisting of insoluble, non-bioavailable microaggregates
Implementation Method 2
forming soluble micellar nanoaggregates of 50-200 nm, which are easily absorbed
Data Source
AI summary
Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.